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DOI 10.1016/j.ccr.2010.10.032SUMMARYIdentification of molecular pathways essential for cancer stem cells is critical for understanding the under-
lying biology and designing effective cancer therapeutics. Here, we demonstrated that b-catenin was acti-
vated during development of MLL leukemic stem cells (LSCs). Suppression of b-catenin reversed LSCs to
a pre-LSC-like stage and significantly reduced the growth of humanMLL leukemic cells. Conditional deletion
of b-catenin completely abolished the oncogenic potential of MLL-transformed cells. In addition, established
MLL LSCs that have acquired resistance against GSK3 inhibitors could be resensitized by suppression of
b-catenin expression. These results unveil previously unrecognized multifaceted functions of b-catenin in
the establishment and drug-resistant properties of MLL stem cells, highlighting it as a potential therapeutic
target for an important subset of AMLs.INTRODUCTION
Molecular dissection of oncogenic processes that convert nor-
mal cells into cancer cells is critical for understanding transfor-
mation mechanisms and for designing effective therapeutics.
Although significant progress has been made in recent years in
isolating tissue-specific cancer stem cells (CSCs) from patient
samples (Ailles and Weissman, 2007; Gupta et al., 2009), very
little is known about the natural history and molecular pathways
responsible for the oncogenic conversion and establishment of
CSCs. In acute myeloid leukemia (AML) where leukemic stem
cells (LSCs) have been functionally defined (Bonnet and Dick,
1997; Lapidot et al., 1994), we and others have previously shown
that fusion proteins encoded by Mixed Lineage Leukemia (MLL)
gene acting as an initiating event can convert normal murine
hematopoietic stem cells (HSCs) or myeloid progenitors into
AML pre-LSCs (Cozzio et al., 2003; So et al., 2003) by aberrant
recruitment of histone modification enzymes such as Dot1L
(Okada et al., 2005) and Prmt1 (Cheung et al., 2007) that medi-
ates epigenetic reprogramming to confer stem cell-like proper-Significance
Multiple genetic and/or epigenetic events are required for devel
renewal and alleged drug-resistant properties for maintenance
the Wnt/b-catenin pathway plays critical roles for establishm
Genetic ablation of b-catenin completely abolished developm
apre-LSC-like stageandsensitized their in vitro and in vivo resp
dispensable fornormal functionofHSCs, is frequently activated
tial functions ofb-catenin forMLL LSCs reveals it as a potential
606 Cancer Cell 18, 606–618, December 14, 2010 ª2010 Elsevier Incties to the transformed cells (Krivtsov et al., 2006, 2008; Zeisig
et al., 2008). In parallel, human pre-LSCs have also recently
been identified in childhood acute lymphoid leukemia carrying
TEL-AML1 fusion, which is capable of generating pre-LSC
clones that may then convert to LSCs with acquisition of addi-
tional genetic or epigenetic events (Greaves and Wiemels,
2003; Hong et al., 2008). The molecular pathways responsible
for the conversion of pre-LSCs to LSCs with unlimited self-
renewal and alleged drug-resistant properties that are believed
to be key for maintenance and reinitiation of the disease during
relapse (Reya et al., 2001) are still a largely unexplored area
critical for not only understanding the biology of the disease
but also designing effective cancer therapeutics.
RESULTS
Characterization of MLL Pre-LSC and LSC-Enriched
Populations
To gain further insights into the potential pathways responsible
for the conversion and establishment of LSCs, we molecularlyopment of leukemic stemcells (LSCs) carrying unlimited self-
and initiation of the disease. Here, we show that activation of
ent of MLL LSCs and conferring drug-resistant properties.
ent of MLL LSCs. Its suppression reversed MLL LSCs to
onses toGSK3 inhibitor treatment.b-Catenin,which is largely
inacutemyeloid leukemia (AML); thus, identificationofessen-
therapeutic target for selective eradication of AML stemcells.
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Figure 1. Characterization of MLL Pre-LSC and LSC-Enriched Populations
(A) Schematic diagram illustrating the leukemogenic assay.
(B) MLL-ENL LSCs induce leukemia in mice with significantly shorter latency than pre-LSCs (n = 10 for each cell line). Control indicates mice injected with normal
bone marrow cells only.
(C) MLL pre-LSC and LSC-enriched populations had similar cloning efficiencies as determined by the replating assay in methylcellulose medium. Data represen-
tative of three independent experiments are shown. There was no significant difference, p > 0.05.
(D) LDAs demonstrated that pre-LSCs and LSCs have similar frequencies of leukemia-initiating cells. Dotted lines show 95% confidence intervals.
(E) MLL LSC-enriched population exhibited a higher proliferation rate than pre-LSCs in OP9 stroma coculture. Data representative of three independent exper-
iments are shown ± SD *p < 0.05.
(F) Cytokine-dependence assay in methylcellulose showed differences in cytokine requirements between MLL pre-LSC and LSC-enriched populations.
Data from three experiments are shown + SD *p < 0.05.
Cancer Cell
b-Catenin in MLL Leukemia and Drug Resistancedissected and compared the cell populations enriched in MLL
pre-LSCs and LSCs, respectively, in our stepwise murine model
system (Figure 1A) (So et al., 2003; Somervaille andCleary, 2006;
Wong et al., 2007; Zeisig and So, 2009). In this model, pre-LSCs
were identified as early transduced primary cells carrying the
initiating event and endowed with the ability to induce leukemia
in vivo with a long latency (Figures 1A and 1B), whereas LSCsCanwere defined as leukemic cells harvested from primary mice
transplanted with pre-LSCs that had then acquired additional
events and were capable of inducing leukemia in secondary
mice with a very short latency (Figures 1A and 1B). Despite a
major difference in latencies for leukemia induction (pre-LSCs
mean survival: 122 ± 19 days; LSCs mean survival: 15 ±
1 days) (Figure 1B), MLL pre-LSC and LSC-enriched populationscer Cell 18, 606–618, December 14, 2010 ª2010 Elsevier Inc. 607
Table 1. Summary of LDA Results
Frequency of
Target Cells
95% Confidence
Interval
Murine MLL leukemic cells
—Pre-LSCs 1 in 70,218 26,214–188,087
—LSCs 1 in 67,505 34,600–131,704
Human MLL LTC-IC
—MLL-1 Empty Vector 1 in 41 28–60
—MLL-1 sh1D 1 in 102 71–148
—MLL-1 sh22 1 in 138 96–200
—MLL-2 Empty Vector 1 in 948 528–1703
—MLL-2 sh1D 1 in 6710 1667–27,010
—MLL-2 sh22 1 in 8930 1805–44,194
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b-Catenin in MLL Leukemia and Drug Resistanceexhibited similar morphology and immunophenotypes, and
induced AML with very similar, if not identical, phenotypes (see
Figures S1A–S1C available online). Most importantly, MLL pre-
LSC and LSC-enriched populations had similar (12%–15%)
cloning efficiency, which has been previously shown to directly
correlate with the abundance of CSCs (Somervaille and Cleary,
2006) (Figure 1C). This is further confirmed by the observa-
tion of similar cloning efficiency of c-Kit+/Mac-1+/Gr1+ cells of
these two populations, as determined by the single cell-sorting
approach (18%–22%) (Figure S1D). To finally assess the fre-
quency of stem cells in these two populations, in vivo transplan-
tation experiments in combination with limiting dilution assays
(LDAs) were performed (Hu and Smyth, 2009). Consistent with
the results from in vitro clonogenic assay, MLL pre-LSC and
LSC-enriched populations possessed very similar frequency of
leukemia-initiating cells (approximately 1 in 70,000 versus 1 in
67,000, respectively), and the modest difference was not statis-
tically significant (p = 0.94) (Figure 1D, and Table 1; Table S1).
The frequency of MLL pre-LSCs was in the same range as one
previously reported for a different MLL fusion (MLL-AF9, 1 in
66,000) (Somervaille and Cleary, 2006). The frequency of LSCs
was also consistent with the frequency determined for human
AML stem cells (1 in 10,000–10,000,000) (Kennedy et al., 2007)
and those reported for MOZ-TIFII retroviral-transplanted murine
model (1 in 10,000–100,000) (Huntly et al., 2004). Despite the
similar frequency of stem cells in these two populations, the
MLL LSC-enriched population displayed much faster prolifera-
tive rate and was less dependent on cytokines (Figures 1E and
1F). Collectively, these results suggest important qualitative
differences between MLL pre-LSCs and LSCs.
Activation of the Wnt/b-Catenin Pathway
in the MLL LSC Population
To identify pathways that are potentially responsible for the
difference, we performed global expression analysis of MLL
pre-LSC and LSC-enriched populations. Although their expres-
sion profiles exhibited a very high degree of similarity, pre-
LSCs and LSCs did cluster together within their corresponding
subgroups. With a 1.5-fold change cutoff, about 1% (<400) of
the genes were differentially expressed between MLL pre-LSC
and LSC-enriched populations (Figure S2A and Table S2). Meta-
core software-based pathway analysis on both grouped and
matched pair comparisons consistently revealed that multiple608 Cancer Cell 18, 606–618, December 14, 2010 ª2010 Elsevier Inccritical components of Wnt signaling were activated in MLL
LSCs as compared with pre-LSC-enriched populations
(Table S2). By RT-qPCR we confirmed upregulation of all these
components, including Wnt receptors, frizzled 4/6 as well as
their nuclear target, cyclin D2 in MLL LSC-enriched populations
(Figure 2A; Figure S2Band Table S2). In addition, MLL LSCs also
had elevated level of the key mediator of nuclear Wnt signaling,
the b-catenin protein (Figure 2B; Figure S2C). Because b-catenin
was previously shown to promote self-renewal of normal HSCs,
its expression in lineage-depleted (early) hematopoietic progen-
itors and lineage-positive (late) mature cells was determined
(Figure 2B; Figure S2C). Lineage-negative progenitor cells
expressed high levels of b-catenin, which were downregulated
during differentiation into lineage-positive cells, consistently
suggesting that a higher level of b-catenin may help in maintain-
ing the stemness of hematopoietic cells. To assess the nuclear
distribution of activated b-catenin in MLL pre-LSC and LSC pop-
ulations, immunofluorescent staining using antibody specific for
the active form of b-catenin (i.e., non-phosphorylated on Ser37
or Thr41) was performed and showed that a significant portion
of LSCs expressed high levels of activated nuclear b-catenin
as compared to pre-LSCs, which predominately expressed low
level of nuclear b-catenin (Figures 2C and 2D). These differences
were statistically significant (p < 0.05). To further demonstrate
that nuclear b-catenin was indeed transcriptionally active, MLL
LSC and pre-LSC populations were transduced with a Wnt
pBARVS reporter, where expression of Venus eYFP was driven
by 12 copies of TCF consensus-binding sites (Biechele and
Moon, 2008). As a result, although the Wnt reporter exhibited
aweak transcriptional activity in theMLL pre-LSC-enriched pop-
ulation, we could detect a significantly higher nuclear b-catenin
activity in the MLL LSC-enriched population (Figure 2E). The
specificity of the assaywas further confirmed by: (1) replacement
of the Wnt reporter with an identical reporter carrying mutated
TCF consensus-binding sites that resulted in a complete abroga-
tion of the YFP signal (Figure 2E); and (2) human HEK293 cells
carrying the Wnt reporter transfected together with an exoge-
nous b-catenin, resulting in strong transcriptional activity and
expression of the eYFP reporter (Figure S2D). Consistently,
both the mRNA and protein expression of its downstream target,
cyclin D2 (Huang et al., 2007), were elevated in LSCs relative to
pre-LSC-enriched populations (Figure 2F; Figure S2B). Thus,
these results support a differential activation of theWnt-signaling
pathway upon progression from MLL pre-LSCs to LSCs.
Suppression of b-Catenin Expression Delayed
MLL Leukemia
To determine its functional significance in acute leukemogen-
esis, b-catenin in MLL-LSCs was specifically knocked down
by an shRNA approach. Reduction of b-catenin expression at
both mRNA (85%) and protein (90%) levels (Figures 3A and
3B; data not shown) did not significantly alter the morphology
or immunophenotype of LSC-enriched populations (Figures S3A
and S3B). However, it diminished the in vitro cloning efficiency
(Figure 3C), cytokine independence in the presence of only
stem cell factor (SCF) or interleukin (IL)-6 (Figure 3D), and signif-
icantly delayed the disease latency of LSC (Figure 3E), which
were reminiscent of the characteristics of pre-LSCs. Moreover,
secondary transplantation experiments revealed that b-catenin.
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Figure 2. Differential Activation of Wnt/b-
Catenin Pathways in MLL LSCs Is Critical
for Their Leukemogenic Functions
(A) RT-qPCR validation of differentially expressed
genes related toWnt-signaling pathways identified
by global expression array analysis (Figure S2
and Table S2). Data from three experiments are
shown ± SD.
(B) Upregulation of total b-catenin in LSC-enriched
population compared to pre-LSCs and lineage-
positive (Lin+) and lineage-negative (Lin) cells
as determined by western blot.
(C) LSC-enriched population demonstrated higher
levels of active nuclear nonphosphorylated b-cat-
enin as determined by immunofluorescence.
(D) Quantification of cells with low, medium,
or high levels of nonphosphorylated b-catenin
as determined by immunofluorescence. Several
fields of cells were scored from two independent
experiments ± SD *p < 0.05. Scale bar, 10 mm.
(E) Differential upregulation of pBARVS reporter in
MLL LSC-enriched population. Average median
fluorescent intensities (MFIs) were derived from
two independent experiments normalized with
the copy number of the reporter in the cells deter-
mined by qPCR on genomic DNA. Pre-LSC
normalized MFI = MFI: 990/relative copy no.:
127 = 7.87; and LSC normalized MFI = MFI:
9800/relative copy no.: 458 = 21.83. pfuBARVS
construct with point mutation in TCF binding sites
was also used in the assay and exhibited very
similar baseline activity as the untransduced
controls.
(F) Upregulation of cyclin D2 protein in LSC-
enriched population as determined by western
blot.
Cancer Cell
b-Catenin in MLL Leukemia and Drug Resistanceknockdown also significantly compromised the leukemogenic
potential of MLL LSCs, which could otherwise efficiently induce
leukemia with a very brief latency and with complete penetrance
(Figure 3F). Together with the expression data, these results
suggest that activation of b-catenin pathways is functionally
critical for the development of LSCs.
b-Catenin Is Required for the Establishment
of MLL LSCs
To further test this hypothesis, we conditionally deleted Ctnnb1
alleles encoding b-catenin at the early pre-LSC stage usingCancer Cell 18, 606–618, Dfloxed Ctnnb1 bone marrow cells to
determine if MLL LSCs could still be es-
tablished in the absence of b-catenin (Fig-
ure 4A). To minimize any long-term toxic
effect due to the persistent expression
of Cre recombinase, a self-inactivating
‘‘hit-and-run’’ Cre (Silver and Livingston,
2001) was introduced to MLL-ENL-trans-
duced cells. By transient expression of
Cre, floxed Ctnnb1 was deleted in the
bone marrow cells and resulted in a com-
plete loss of b-catenin protein expression
(Figures 4B and 4C). As determined by
in vitro serial replating assays, MLL-ENLstill transformed b-catenin-deficient primary hematopoietic cells
and generated pre-LSCs in vitro, albeit with lower cloning effi-
ciency as compared with MLL-ENL-transformed cells, which
carried intact floxed Ctnnb1 alleles (Figure 4D). However, it
was notable that deletion of b-catenin significantly increased
the populations of pre-LSCs that lost the expression of c-Kit,
which has been proposed as a marker for enrichment of MLL
LSCs (Figure 4E; Figure S4) (Somervaille and Cleary, 2006; Som-
ervaille et al., 2009). To further assess the leukemogenic poten-
tial of these pre-LSCs in initiating leukemia, the cells were serially
transplanted into syngeneic mice. MLL pre-LSCs with intactecember 14, 2010 ª2010 Elsevier Inc. 609
C D
0
20
40
60
80
100
120
140
160
180
SC
F+
IL
-3
+I
L-
6
+
G
M
-
CS
F
SC
F 
on
ly
IL
-3
 o
nl
y
IL
-6
 o
nl
y
G
M
-
CS
F 
on
ly
No
ne
Cytokines
R
e
l
a
t
i
v
e
 
n
u
m
b
e
r
 
o
f
 
c
o
l
o
n
i
e
s
LSC Empty Vector
LSC β-catenin KD
*
*
0
20
40
60
80
100
120
LSC
Empty
Vector
LSC
β-catenin
KD
R
e
l
a
t
i
v
e
 
n
u
m
b
e
r
 
o
f
 
c
o
l
o
n
i
e
s *
FE
Time (weeks)
D
i
s
e
a
s
e
-
f
r
e
e
 
s
u
r
v
i
v
a
l
 
(
%
)
D
i
s
e
a
s
e
-
f
r
e
e
 
s
u
r
v
i
v
a
l
 
(
%
)
0
20
40
60
80
100
0 5 10 15
LSC Empty Vector
LSC β-catenin KD
p=0.04055
Time (weeks)
LSC Empty Vector
LSC β-catenin KD
p=0.0039
BA
0 2 4 6 8 10
0
20
40
60
80
100
R
e
l
a
t
i
v
e
 
β-c
a
t
e
n
i
n
e
x
p
r
e
s
s
i
o
n
0
0.2
0.4
0.6
0.8
1
1.2
LSC 
Empty 
Vector
LSC 
β-catenin
KD
β-catenin
LS
C 
Em
pt
y 
ve
ct
o
r
LS
C 
β-c
a
te
ni
n
KD
β-actin
Figure 3. Knockdown of b-Catenin Inhibits Colony Formation and Delays Onset of Leukemia Induced by LSC
(A) RT-qPCR validation of knockdown (KD) of b-catenin. Data representative of three experiments are shown ± SD.
(B) Reduced total b-catenin protein expression after knockdown as determined by western blotting. Knockdown of b-catenin reduced (C) cloning efficiency (data
from three independent experiments) and (D) cytokine independence of LSC-enriched population ± SD *p < 0.05. Reduced level of b-catenin delayed the onset of
leukemia induced byMLL LSCs in both (E) primary (Empty Vector, n = 16; b-catenin KD, n = 20), and (F) secondary transplant mice (Empty Vector, n = 5; b-catenin
KD, n = 4).
Cancer Cell
b-Catenin in MLL Leukemia and Drug Resistancefloxed Ctnnb1 alleles were able to efficiently induce leukemia
in primary and secondary transplanted mice, indicating an effi-
cient conversion of pre-LSCs into full-blown LSCs in the pres-
ence of b-catenin. However, the presence of floxed alleles might
have a mild impact on the disease progression, as suggested by
the relatively small change in disease latency (from 9 to 7 weeks
on average) upon the secondary transplant (Figure 4F). In con-
trast, MLL pre-LSCs with a complete deletion of b-catenin failed
to induce leukemia and could no longer be detected in the recip-
ients when mice were sacrificed 20 weeks after transplantation
(Figure 4F; data not shown). Together, these results reveal an
essential role for b-catenin in the establishment of MLL LSCs.
Suppression of b-Catenin Impaired Human MLL Cells
Although the results from murine models provided strong
evidence for a critical function of b-catenin in establishment of
murineMLL LSCs, it was not clear whether b-catenin also played
an important role in human leukemia. To this end, functional
assays were performed using specific shRNAs in combination
with three different human systems, including human MLL
leukemic cell lines, primary AML cells carrying MLL fusion, and
human CD34+ cord blood transduced with MLL fusion. Using
shRNAs that effectively knocked down the expression of b-cat-610 Cancer Cell 18, 606–618, December 14, 2010 ª2010 Elsevier Incenin (Figures S5A–S5D), we showed that suppression of b-cate-
nin significantly inhibited the proliferation potentials of HB1119
human leukemic cells carrying MLL-ENL fusion, but not on
NB4 leukemic cells carrying the PML-RARa fusion (Figure 5A).
Both HB1119 and NB4 leukemic cells were capable of form-
ing leukemic colonies in methylcellulose that could also be seri-
ally replated (Figure 5B). Downregulation of b-catenin expres-
sion severely inhibited the colony formation ability of HB1119
leukemic cells, whereas b-catenin knockdown did not have
significant effect on NB4 leukemic cells (Figure 5B). Suppression
of b-catenin exhibited an even more pronounced effect on
MLL leukemic cells for their serial replating ability (Figure 5B),
which has been used as an in vitro surrogate assay for self-
renewal.
Because long-term culturing of leukemic cell lines may have
introduced irrelevant genetic/epigenetic events that can com-
plicate the overall interpretation, we also examined the role of
b-catenin in patients’ primary cells carrying MLL fusions. MLL
leukemic cells from two different patients (MLL-1 and MLL-2)
were transduced with vector control or b-catenin shRNAs
before they were subjected to multiple functional assays,
including colony formation, MS5 replating, and LDA. As a result,
primary MLL leukemic cells transduced with b-catenin shRNAs.
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Figure 4. b-Catenin Is Critical for the Establishment of MLL LSCs
(A) Schematic diagram illustrating experimental approaches to assess the functional requirement of b-catenin for establishment of MLL LSCs.
(B) c-Kit+ cells derived fromwild-type (lane 1), orCtnnb1fl/fl/Rosa26 floxed-stop-LacZ (lanes 2–4) bonemarrows were transduced with retroviruses carryingMLL-
ENL and self-inactivating Cre. After the second plating, they were incubated with FDG substrate, which was converted to fluorescein by b-galactosidase activity
for FACS. Genotyping of co-transduced cells derived from wild-type bone marrow (lane 1), Ctnnb1fl/fl/Rosa26 floxed-stop-LacZ bone marrow prior to FACS
(lane 2), post-FACS with fluorescein-negative (lane 3), or fluorescein-positive (lane 4) cells were indicated. Sorted fluorescein-positive cells have Cre-mediated
deletion of Ctnnb1, whereas fluorescein-negative population maintained the floxed Ctnnb1 alleles.
(C) Western blot analysis of sorted cells confirmed a complete loss of total b-catenin protein expression in cells derived from fluorescein-positive but not fluo-
rescein-negative cells.
(D) Deletion of b-catenin in MLL-ENL transformed cells inhibited colony formation. Representative data from three independent experiments are shown.
(E) Flow cytometric analysis revealed significant loss of c-Kit expression in MLL-transformed cells derived from b-catenin deficient bone marrow.
(F) Absence of b-catenin abolished in vivo oncogenic potential of MLL-ENL transformed cells (Ctnnb1fl/fl + MLL-ENL pre-LSC n = 11; Ctnnb1del + MLL-ENL pre-
LSC n = 15; Ctnnb1fl/fl + MLL-ENL LSC n = 5). Ctnnb1fl/fl + MLL-ENL pre-LSCs versus Ctnnb1del + MLL-ENL pre-LSCs p = 0.0001. Ctnnb1fl/fl + MLL-ENL pre-
LSCs versus Ctnnb1fl/fl + MLL-ENL LSCs p = 0.2744.
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b-Catenin in MLL Leukemia and Drug Resistanceyielded a significantly reduced number of colony-forming unit
(CFU)-blasts (Figure 5C), indicating that suppression of b-cate-
nin negatively impacts the cloning efficiency of MLL leukemic
cells. A MS5-replating assay was then employed to determine
the effect of b-catenin on relatively long-term proliferative poten-
tials of primaryMLL cells. Although suppression of b-catenin had
little effect on primary MLL leukemic cells in the first 3 weeks ofCanMS5 coculture, a significant reduction of proliferative potentials
was observed at 4–5 weeks (Figure 5D), consistent with
a putative role of b-catenin in maintaining self-renewal of MLL
LSCs. Next, LDAs were performed to determine the frequency
of leukemic long-term culture initiating cells (LTC-ICs) upon
3 weeks culture followed by another 3 weeks on MS5 coculture.
The frequency of LTC-ICs in MLL-1 and MLL-2 transduced withcer Cell 18, 606–618, December 14, 2010 ª2010 Elsevier Inc. 611
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Figure 5. b-Catenin Knockdown Impairs Human MLL Leukemic Cells
(A) b-Catenin knockdown impairs proliferation of HB1119 cells carrying MLL-ENL fusion gene. Cell proliferation was evaluated using MTS assay after 3, 5,
and 7 days of culture (sh1D versus Empty Vector, p = 0.048; sh19 versus Empty Vector, p = 0.0032). Data from three independent experiments are shown ±
SD. *p < 0.05.
(B) b-Catenin knockdown significantly reduced the cloning efficiency as well as replating ability of HB1119 cells. The number of colonies after each round was
normalized against Empty Vector control. Data from three independent experiments are shown ± SD *p < 0.05.
(C) b-Catenin knockdown significantly reduces the frequency of CFU blasts in patients MLL-1 (left panel) and MLL-2 (right panel). Cells were plated in methyl-
cellulose at day 1 after shRNA transduction and counted at day 14. Data for all conditions were then normalized to Empty Vector control using the percentages of
GFP+ cells assessed at day 4 (transduction efficiency). Data from three experiments are shown ± SD. *p < 0.05.
(D) b-Catenin knockdown significantly impairs the proliferative potential of AML cells of patient MLL-1 (left panel) and MLL-2 (right panel) between weeks 4 and 5
of co-culturing on MS5 stromal layer. GFP percentages for all conditions are shown in relative to the GFP+ content at day 4, which were set at 100% (Lei et al.,
2010). Data from three experiments are shown ± SD. *p < 0.05.
(E and F) Limiting dilution analysis at week 6 of coculture of patients’ cells (MLL-1 in E, MLL-2 in F) on MS5 stromal layer indicated that b-catenin knockdown
significantly decreased the frequency of long-term initiating cells (also see Table 1).
(G) b-Catenin knockdown impaired proliferation of human CD34+ cord blood (hCB) carrying MLL-ENL fusion gene. Cell proliferation was evaluated by enumer-
ation of viable cells with trypan blue every week for 3 weeks. Data from three experiments are shown ± SD. *p < 0.05.
(H) b-Catenin knockdown reduced the cloning efficiency of MLL-ENL transduced hCB. Number of colonies were normalized versus Empty Vector control (sh1D
versus Empty Vector; *p < 0.05). All the data are the means of at least three independent experiments ± SD.
Cancer Cell
b-Catenin in MLL Leukemia and Drug Resistancevector control was 1 in 41 and 1 in 948, respectively (Figures 5E
and 5F; Table 1). However, specific knockdown b-catenin
expression resulted in an average of 3- and 8-fold reduction of
LTC-IC frequency in MLL-1 and MLL-2 patients, respectively
(Figures 5E and 5F; Table 1), suggesting that b-catenin is
required for maintenance of LTC-ICs.612 Cancer Cell 18, 606–618, December 14, 2010 ª2010 Elsevier IncFinally, to assess the potential impact of b-catenin during the
early stages of MLL leukemia development, CD34+ human
hematopoietic cells derived from cord blood were transduced
with MLL-ENL together with vector control or b-catenin shRNA
and tested for proliferation and colony formation abilities. MLL-
ENL transduced human CD34+ hematopoietic cells efficiently.
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Figure 6. Acquired Drug Resistance of the
MLL LSC-Enriched Population to GSK3
Inhibitors Is Dependent on b-Catenin
(A) MLL-LSCs acquired additional drug resistance
to GSK3 inhibitors. Differential growth inhibitory
effects of LiCl on MLL pre-LSC and LSC-enriched
populations after 24 hr treatment. E2A-PBX trans-
formed primary cells were used as a control. Data
are means from two experiments ± SD. *p < 0.05.
(B) GSK3 inhibitors, LiCl, SB216763, and GSK3IX
(BIO) preferentially inhibited the proliferation of
MLL pre-LSC but not LSC-enriched populations
over 7 days in OP9 coculture. Data are means
from two experiments ± SD. *p < 0.05.
(C) Modest effect of GSK3 inhibitors on MLL LSCs
transduced with Empty Vector control. Represen-
tative data are shown from two experiments.
There was no significant difference, p > 0.05.
(D) Reduction of the b-catenin sensitized MLL
LSC-enriched population to GSK3 inhibitors.
Representative data are shown from two experi-
ments ± SD. *p < 0.05.
(E) GSK3 inhibitor, lithium carbonate, delayed
onset of leukemia in mice transplanted with MLL
LSCs carrying b-catenin shRNA, but not vector
control (Empty Vector, n = 7; b-catenin KD, n = 8).
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b-Catenin in MLL Leukemia and Drug Resistanceproliferated and formed colonies in vitro (Figures 5G and 5H).
However, b-catenin knockdown significantly suppressed their
proliferation on MS5 coculture (Figure 5G) as well as their clono-
genic potentials (Figure 5H). Together with the data from estab-
lished human cell lines and primary AML cells, these results
strongly indicate that b-catenin also plays a critical role in human
MLL leukemic cells.
Suppression of b-Catenin Resensitized GSK3 Inhibitors
Sensitivity of the MLL LSC-Enriched Population
In addition to self-renewal, drug resistance is another important
feature of LSCs that forms the critical hypothesis of LSCs as
a possible source for relapse (Reya et al., 2001). GSK3 inhibitors
have recently been identified as highly specific and effective
inhibitors to MLL transformed cells, partially via activation ofCancer Cell 18, 606–618, Dp27 cell cycle inhibitor (Wang et al.,
2008). However, inhibition of GSK3 will
at the same time suppress proteasome-
mediated inactivation of b-catenin that
may counteract their growth inhibitory
effect. This led to our hypothesis that
GSK3 inhibitors would become less
effective in the cells that had high levels
and are driven by active b-catenin func-
tions such as MLL LSCs. Therefore, we
compared the sensitivity of MLL pre-
LSCs and LSCs with differential activa-
tion of Wnt/b-catenin signaling to various
GSK3 inhibitors at the same concentra-
tion as employed in the previous study
(Wang et al., 2008). E2A-PBX trans-
formed cells, which have been previously
shown to be resistant to GSK3 inhibitors,were used as a control (Wang et al., 2008). As expected, E2A-
PBX transformed cells were refractory to LiCl treatment and
exhibited only modest inhibition (Figure 6A; Figure S6A). In
contrast, the MLL pre-LSC-enriched population was sensitive
to LiCl, which rapidly led to a significant cell death within the first
24 hr, as evidenced by its increased sub-G1 population (Fig-
ure 6A; Figures S6A–S6C; data not shown). Remarkably, the
MLL LSC-enriched population was refractory to the LiCl
treatment in both cytokine-supplemented culture and OP9
coculture systems (Figures 6A and 6B; Figures S6A–S6C).
Similar but less pronounced inhibitions were also obtained
using different GSK3 inhibitors (Figure 6B), indicating that MLL
LSCs have acquired additional resistance to GSK3 inhibition.
To determine if activation of b-catenin contributed to the resis-
tance, we knocked down b-catenin in the MLL LSC-enrichedecember 14, 2010 ª2010 Elsevier Inc. 613
Figure 7. Schematic Diagram Illustrates the
Potential Function of b-Catenin during
Development of MLL LSCs
MLL fusion transforms normal hematopoietic cells
into pre-LSCs expressing low level of b-catenin
(b-catlo). Pre-LSCs with enhanced self-renewal
property remains sensitive to GSK3 inhibitor
(GSK3i) and induces leukemia in mice with long
disease latency. Cooperative genetic and/or
epigenetic events including upregulation of Wnt/
b-catenin pathway (b-cathi) convert MLL pre-
LSCs into LSCs, which can become GSK3 inhib-
itor resistant and induce leukemia with very
brief latency. Although b-catenin is required for
the establishment of MLL LSCs, knockdown of
the expression of b-catenin (b-cat KD) in LSCs
partially reverses them to a pre-LSC-like stage.
Cancer Cell
b-Catenin in MLL Leukemia and Drug Resistancepopulation and repeated the drug treatment. As expected,
LSCs transduced with vector control were refractory to GSK3
inhibitor treatment (Figure 6C). However, b-catenin knockdown
apparently sensitized MLL LSCs to GSK3 inhibitors, which re-
sulted in 30%–60% suppression of proliferation within 24 hr
(Figure 6D). To further investigate if reduced levels of b-catenin
had a long-term in vivo effect on the MLL LSC, LSC-enriched
population transduced with vector control or b-catenin shRNA
was injected into syngeneic mice, which were then fed with
normal or Li2CO3 diet. As a result, mice transplanted with the
control MLL LSC population rapidly developed leukemia,
regardless of the treatment, which established that they were
resistant to the inhibitor (Figure S6D). In contrast, the Li2CO3
diet delayed the disease latency for mice transplanted with
the MLL LSC-enriched population expressing the b-catenin
shRNA (Figure 6E ; Figure S6E) and, therefore, further sup-
ported that b-catenin contributes to the observed drug resis-
tance of MLL LSCs.
DISCUSSION
Although the unlimited self-renewal and acquired drug resis-
tance have been two salient properties of CSCs, very little is
known about the underlying mechanisms. In this study, we
propose that the activated Wnt/b-catenin pathway is critical for
the development and drug-resistant property of MLL LSCs.
It is not completely clear at which exact stage (e.g., pre-LSCs
versus early LSCs) b-catenin is activated. Given the similar
cloning efficiencies and stem cell frequencies yet vastly different
disease latencies induced by these two studied populations, we
favor the hypothesis that the Wnt-signaling pathway is progres-
sively activated during progression from pre-LSCs to LSCs,
but we cannot exclude the possibility that a small number of
MLL pre-LSCs primed with activated Wnt signaling expanded
exponentially and became dominant during clonal evolution.
Although b-catenin is preferentially activated in LSCs, it is likely
that a low level of b-catenin is also required for MLL pre-LSCs
(Figure 7). This is consistent with the observation that although
MLL pre-LSCs and LSCs had similar stem cell frequencies:
(1) significant knockdown of the expression of b-catenin in MLL
LSCs to a level lower than pre-LSCs resulted in further reduction
of colony formation potential (Figure 3); (2) b-catenin knockdown614 Cancer Cell 18, 606–618, December 14, 2010 ª2010 Elsevier Incin MLL pre-LSCs reduced their cloning efficiency (data not
shown); and (3) deletion of b-catenin in the MLL pre-LSC stage
led to reduction of in vitro cloning ability (Figure 4). Although
different levels of b-catenin may be required for MLL pre-LSCs
and LSCs, ablation of b-catenin at an early transformation stage
completely abolished the leukemogenic potential of MLL-trans-
duced cells, clearly indicating that b-catenin is essential for
establishment of MLL LSCs from normal hematopoietic cells
(Figure 7). Importantly, the role of b-catenin is also conserved
in human MLL cells. We demonstrated that inhibition of b-cate-
nin significantly suppressed human leukemic cells carrying
MLL fusion in three different model systems. Consistently with
the murine data, b-catenin seems to be involved at both early
(in CD34+ cells transduced with MLL fusion) and late stages of
the leukemic development (in MLL primary leukemic cells at
the disease presentation). This function is also preserved even
in a long-term passage cell line carrying MLL fusion, suggesting
a highly conserved and stable requirement of b-catenin for MLL
leukemic cells.
MLL leukemia, particularly in infants, is one of the most
aggressive and worst prognostic subgroups among all hemato-
logical malignancies. Recent studies showed that its transforma-
tion is largely independent of Hedgehog and Bmi1 signaling
(Hofmann et al., 2009; and unpublished data). Identification of
essential functions of b-catenin in MLL leukemia not only sheds
light on the biology of the disease but also provides further
opportunities for the development of more effective cancer ther-
apeutics. A very recent study has sophisticatedly shown that
GSK3 inhibitors target MLL leukemic cells via suppression of
Hox/Pbx/Meis1/Creb activation complex andmay also be effec-
tive on other Hox-activated leukemias (Wang et al., 2010b).
Although these results support the application of GSK3 inhibitors
for targeted therapies in AML, their efficacy at eliminating LSCs
remains to be demonstrated. In contrast to the MLL pre-LSC-
enriched population that was sensitive to GSK3 inhibitor treat-
ment, we showed that MLL LSCs with a high level of nuclear
b-catenin activity were refractory to the inhibitors, suggesting
the presence of potentially counteracting pathways in LSCs
that will allow resistance toward GSK3 or other related inhibitors.
Notably, it is unlikely that b-catenin is the only factor that con-
tributes to the conversion of MLL pre-LSCs to LSCs, but
suppression of b-catenin in established MLL LSCs diminished.
Cancer Cell
b-Catenin in MLL Leukemia and Drug Resistancetheir in vitro cloning efficiency, cytokine independence, in vivo
leukemogenic potential, and also GSK3 inhibitor resistance,
partially reversing them to a pre-LSC-like stage (Figure 7),
providing a strong rationale of targeting b-catenin in MLL
leukemia.
b-Catenin is associated with imatinib resistance in chronic
myeloid leukemia (CML) (Jamieson et al., 2004) and has recently
been shown to be critical for the establishment of aggressive
cutaneous CSCs that express high levels of CD34 (Malanchi
et al., 2008), which is also upregulated in multiple hematological
malignancies including our MLL LSCs (Table S2, and Figures
S2E and S2F). The Wnt/b-catenin pathway has been recurrently
implicated in different forms of AML (Mikesch et al., 2007) and
is activated in self-renewing myeloid progenitors during CML
blast crisis (Jamieson et al., 2004), suggesting that activation
of b-catenin may be a common pathway shared by different
CSCs. However, a complete deletion of b-catenin did not abolish
BCR-ABL induced leukemia (Zhao et al., 2007). b-Catenin-defi-
cient CML cells with LSK phenotypes were compromised in
transplanting the disease to secondary recipients, but mice still
developed transplantable ALL, suggesting a rather limited role
of b-catenin in acute leukemogenesis (Zhao et al., 2007). In
contrast, the current study provides clear evidence and strong
rationales for targeting b-catenin in human acute leukemia asso-
ciated with MLL fusions. This is also echoed by the recent
discovery of an important function of b-catenin in the develop-
ment of murine AML stem cells from normal granulocyte-macro-
phage progenitors (GMPs), where b-catenin is required for
leukemic transformation by Meis1/Hoxa9 or MLL-AF9 fusion
(Wang et al., 2010a). In addition to the functional demonstration
of its role in human MLL leukemia, our findings have also further
defined the multifaceted function of b-catenin in the establish-
ment of MLL LSCs, in particular for the transition from pre-
LSCs to LSCs, and a previously unrecognized function in con-
ferring drug resistance. In contrast to MLL LSCs, b-catenin is
largely dispensable for normal HSCs. Bone marrow cells derived
from mice deficient in b-catenin or even in combination with
g-catenin do not have any obvious hematopoietic defects
under both normal and stress conditions and are capable of fully
reconstituting hematopoietic systems upon bone marrow trans-
plantation into syngeneicmice (Cobas et al., 2004; Jeannet et al.,
2008; Koch et al., 2008). Thus, identification of essential func-
tions of b-catenin in the establishment of MLL LSCs reveals it
as a potential therapeutic target for eradication of AML stem
cells but sparing normal HSCs.EXPERIMENTAL PROCEDURES
Retroviral/Lentiviral Transduction and Transformation Assays
Both RTTAs/LTTAs were performed on primary murine or human hematopoi-
etic cells as previously described, with some modifications (Zeisig and So,
2009; Bonnet, 2009; Schuringa and Schepers, 2009; Wunderlich and Mulloy,
2009).
c-Kit+ cells were isolated from murine bone marrow and were cultured
overnight in R10medium (see Cell Culture details) supplementedwith 20 ng/ml
SCF, 10 ng/ml IL-3, and 10 ng/ml IL-6. Spinoculation using concentrated viral
supernatant was carried out by centrifugation at 800 3 g in the presence of
5 mg/ml polybrene (Sigma-Aldrich, Poole, UK) at 32C for 2 hr. A second spi-
noculation step was performed on the following day. Cells were plated in
M3231methylcellulosemedium (StemCell Technologies, Vancouver, Canada)Cansupplemented with recombinant murine 20 ng/ml SCF, 10 ng/ml IL-3, 10 ng/ml
IL-6, and 10 ng/ml granulocyte macrophage colony-stimulating factor
(GM-CSF) and appropriate selection antibiotic on the following day. Colonies
were scored after 7 days of culture and replated every 7 days. After the third or
fourth round of plating, cells were cultured in R20/20 (see Cell Culture details)
to establish cell lines. All recombinant murine cytokines were purchased from
PeproTech EC, London, UK.
For human cell studies, frozen AML samples were thawed and prestimu-
lated for 4 hr at 37C in Stem Span medium (Stem Cell Technologies) supple-
mented with 20 ng/ml each of recombinant human IL-3, granulocyte-colony-
stimulating factor (G-CSF), and thrombopoietin (TPO) (PeproTech, Rocky Hill,
NJ, USA) and then incubated overnight in Stem Span medium supplemented
with 100 ng/ml SCF, 100 ng/ml Flt3-ligand (Flt3-L), 60 ng/ml IL-3, and 10 ng/ml
TPO in the presence of 4 mg/ml polybrene and of viral particles at a multiplicity
of infection of 30. Cells were then washed and either cocultured on MS5
stromal layer (see LDA section), plated in triplicate in H4330 MethoCult media
(Stem Cell Technologies) for CFU blast leukemic colony assay. For hCB
studies, purification and transduction of hCB cells were performed as previ-
ously described (Wunderlich and Mulloy, 2009). Briefly, density gradient puri-
fied fresh cord blood was selected for CD34+ cells using the human CD34
purification MidiMACS purification kit (Miltenyi Biotec, Bergisch Gladbach,
Germany) and subsequently cultivated in hCB expansion medium (IMDM
supplemented with 10% heat-inactivated fetal calf serum [FCS], 104 M
b-mercaptoethanol [b-ME], antibiotics, and 10 ng/ml each of human recombi-
nant SCF, TPO, Flt3-L, IL-3, and IL-6) for 24 hr at 37C and 5% CO2 prior to
spinoculation at 800 3 g in the presence of 5 mg/ml polybrene at 32C for
2 hr with lentiviral supernatant. At 48 hr after transduction, cells were selected
with puromycin and blasticidin (for MLL fusion) for 72 hr. Cells were subse-
quently plated into (1) H4100 methylcellulose (Stem Cell Technologies)
containing 20% heat-inactivated FCS, 104 M b-ME, 20% IMDM, 2 mM
L-glutamine, and 10 ng/ml each of human recombinant SCF, IL-6, IL-3,
G-CSF (PeproTech EC), and 6 U/ml erythropoietin (EPO) (R&D Systems,
Abingdon, UK) (Wunderlich and Mulloy, 2009); and (2) coculture with irradiated
MS5 stromal cells in long-term culture (LTC) medium (alpha-MEM supple-
mented with heat-inactivated 12.5% FCS, heat-inactivated 12.5% horse
serum [Sigma-Aldrich], 2 mM L-glutamine, 57.2 mM b-ME, and 20 ng/ml
each of human recombinant TPO, IL-3, and G-CSF) (Schuringa and Schepers,
2009). Cultures were kept at 37C and 5% CO2 and replated on new MS5
stroma every week. At nominated time points, cell number and viability
were evaluated with trypan blue or MTS assay using the CellTiter 96 AQueous
One Solution Cell Proliferation Assay kit according to the manufacturer’s
instructions (Promega, Southampton, UK).
Immunofluorescence Staining for Active Nonphosphorylated
b-Catenin
A total of 5 3 104 cells was cytospun onto glass microscope slides and then
fixed with 4% formaldehyde in PBS (pH 7.4) for 30 min on ice. Cells were
washed in 13 phosphate-buffered saline (PBS) and permeabilized and
blocked using 10% FCS/1% bovine serum albumin (BSA)/0.2% TX-100/PBS
for 15 min. Anti-human active nonphosphorylated b-catenin (clone 8E7) (Milli-
pore, Watford, UK) was used at 1:50 dilution in 10% FCS/1% BSA/PBS and
incubated overnight at 4C. Slides were washed three times with PBS and
subsequently incubated with 1:100 donkey anti-mouse FITC diluted in 10%
FCS/1% BSA/PBS for 30 min at room temperature in the dark. Slides were
washed five times at 10 min each with PBS. Slides were incubated with
DAPI at 100 mg/ml in PBS for 5 min at room temperature. Slides were washed
once in PBS for 10 min and briefly air-dried prior to mounting with Vectashield
(Vector Laboratories, Peterborough, UK) and a coverslip. Several fields were
scored for low, medium, and high intensity staining.
b-Catenin Knockdown
All of the shRNAs constructs expressed the GFP marker. pSiren-RetroQ-
b-cateninmurine shRNA and control retroviral constructs were previously pub-
lished (Cawthorn et al., 2007) and were modified to express GFP. For human
shRNAs, pGIPZ lentivirus from OpenBiosystems (Epsom, UK) expressing
both GFP and puromycin markers were used. The target sequences, from 50
to 30, were CAGATGGTGTCTGCTATTGTA (targeting the position 846–866 of
human b-catenin gene sh1D), TAGCTGATATTGATGGACAGT (targeting thecer Cell 18, 606–618, December 14, 2010 ª2010 Elsevier Inc. 615
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GAGTGGTAAA (targeting the position 396–417 of human b-catenin gene
sh22).
b-Catenin/TCF Reporter Assay
Cells were transduced with pBARVS lentiviral reporter, which contains 12 TCF
response elements upstream of b-globin linked to Venus (a variant of eYFP)
(Biechele andMoon, 2008). Cells were spinoculated as described above. Cells
were expanded, and Venus eYFP+ cells were purified by fluorescence-acti-
vated cell sorting (FACS). Genomic DNA was extracted using the DNeasy
Blood & Tissue Kit (QIAGEN). pBARVS copy number was determined by
qPCR using primers described in Supplemental Experimental Procedures.
A standard curve was prepared using serial dilutions of pBARVS plasmid.
Copy number was expressed relative to Gapdh levels, as determined using
TaqMan mouse Gapdh primer/probe control reagents (Applied Biosystems).
A median fluorescence intensity (MFI) and copy ratio were determined from
independent experiments to assess relative levels of nuclear b-catenin activity.
As a control for specificity, the pfuBARVS reporter, which contained mutated
TCF response elements (Biechele and Moon, 2008), was also used to trans-
duce pre-LSCs and LSCs.
LDA
For in vivo LDAs, varying numbers of cells from pre-LSC or LSC-enriched pop-
ulations were transplanted into sublethally irradiated syngeneic mice and
monitored for disease development. For in vitro LDAs, AML samples were
cocultured on MS5 stromal layer in the presence of 20 ng/ml recombinant
human IL-3, G-CSF, and TPO (Schuringa and Schepers, 2009). After 3 weeks,
20 individual wells per condition were assessed and scored for GFP status and
proliferation. AML samples cocultured on MS5 stromal layer were harvested
after trypsinization and analyzed for GFP content in the human CD45+ popu-
lation (mouse antihuman CD45 APC-Cy7; BD PharMingen) at day 3 and from
weeks 1 to 5 using the LSRII cytometer (Becton Dickinson). FlowJo software
(Tree Star, Switzerland) was used for analysis. Replating was done at week
3 with an equal number of GFP+ sorted cells into a new layer of MS5 stroma.
In Vitro Drug Studies
Drug studies were carried out using cells at 43 105 cells/ml in R20/20 or 0.53
104 to 13 105 cells/ml for OP9 coculture in the absence or presence of 10 mM
SB216763 (Sigma-Aldrich), 8 mM lithium chloride (Sigma-Aldrich), and 2 mM
GSK3 inhibitor IX (BIO) (Cayman Chemicals). For cell cycle analysis, cells
were washed in cold PBS and then fixed with ice-cold 70% ethanol for least
30 min at 4C. Fixed cells were washed with SM (PBS; 0.8% FCS) and resus-
pended in 500 ml of 40 mg/ml propidium iodide and 100 mg/ml RNase A (Invitro-
gen) in SM and incubated at 37C for 20 min and analyzed by flow cytometry.
Cell viability was determined with trypan blue.
Animals and Drug Treatment Studies
All experimental procedures were approved by King’s College London, Insti-
tute of Cancer Research, and London Research Institute ethics committees
and conform to the UK Home Office regulations. Ctnnb1fl/fl mice (Brault
et al., 2001) were crossed with the Rosa26 mice reporter line (Soriano,
1999). Compound homozygous mice were used for experiments. For trans-
plantation experiments, C57BL/6 or SJL mice were given 8.5 Gy total body
g-irradiation and injected intravenously with up to 1 3 106 test cells mixed
with 0.2 3 106 C57BL/6 or SJL bone marrow mononuclear cells. For drug
studies, lithium carbonate treatment commenced on the day after irradiation
and injection of cells. Mice were given 0.4% lithium carbonate containing
chow (LabDiet 5002; PMI Nutrition International) with 0.9% saline every other
day for 1–2 weeks to minimize toxicity from lithium-induced polyuria. Mice
were then subsequently maintained on 5 days of lithium carbonate diet and
saline alternated with 2 days regular diet and water for the remainder of the
experiment.
Microarray Studies
Total RNA from pre-LSCs, LSCs, and clonal derivatives of each were pro-
cessed using protocols derived from the Affymetrix GeneChip Whole Tran-
script (WT) Sense Target Labeling Assay Manual. Affymetrix GeneChip Mouse
Exon 1.0ST arrays were hybridized and scanned with an Affymetrix GeneChip616 Cancer Cell 18, 606–618, December 14, 2010 ª2010 Elsevier Incscanner 3000 running GCOS software. Analyses of whole transcript expres-
sion levels were carried out. Normalized data were then filtered for genes dis-
playing a fold change of 1.5 or greater between pre-LSCs and LSCs. Metacore
pathway analysis and data mining software (GeneGo) were used to identify
pathways of interest.
Real-Time Quantitative PCR
RT-qPCR was performed using SYBR Green reagents on an ABI 7900HT Fast
Real-Time PCR System (Applied Biosystems) using primers listed in Supple-
mental Experimental Procedures. Relative expression levels were calculated
using the 2-DDCT method (Schmittgen and Livak, 2008).
Purification of Ctnnb1del Cells
Fluorescein di-b-galactopyranoside (FDG) (Invitrogen) was used as a fluoro-
genic substrate for the Rosa26 reporter according to the manufacturer’s
instructions. Fluorescein-positive and -negative cells were purified by FACS.
Ctnnb1del and Ctnnb1fl alleles were detected by PCR as previously described
(Brault et al., 2001) using primers listed in the Supplemental Experimental
Procedures.
Cloning Efficiency and Cytokine-Dependence Assays
A total of 1 3 103 cells was plated into M3231 methylcellulose medium (Stem
Cell Technologies) containing four cytokines or single cytokines. Cytokines
were used at the concentrations as described previously. Colony numbers
were enumerated on day 7. Cloning efficiency was also determined by sorting
single cells into wells of 96-well plates that contained 100 ml cytokine-supple-
mented M3231 methylcellulose.
Western Blot Analysis
Membraneswere probedwith anti-b-catenin antibody (clone 14/Beta-Catenin)
(BD) or anti-Cyclin D2 Ab-2 (clone DCS-3.1) (Thermo Fisher Scientific).
Western blots were scanned and quantified using ImageJ software from the
National Institutes of Health.
Cell Culture
All murine myeloid cell lines were maintained in R20/20 medium (RPMI 1640,
20% FCS, 20%WEHI-conditioned medium as a source of IL-3, 2 mM L-gluta-
mine, 100 U/ml penicillin, and 100 mg/ml streptomycin). Conditioned medium
was harvested from WEHI cells grown to confluency over 3 days in R10
medium (RPMI 1640, 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and
100 mg/ml streptomycin) and sterile filtered using a 0.22 mm filter. OP9 stroma
cells were maintained in alpha-MEM medium supplemented with 20% FCS,
2mML-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. For cocul-
ture studies, OP9 cells were irradiated at 30 Gy to inhibit cell growth and plated
at a density of approximately 1 3 104 cells/cm2 in 12-well plates. Irradiated
cells were incubated overnight before hematopoietic cells were seeded. The
medium was replenished every other day by a half-medium change.
Flow Cytometric Analysis of Murine Cell Lines and Leukemic Mice
Protocols and reagents used were as previously described (Yeung and So,
2009; Zeisig and So, 2009).
Statistical Analysis
Two-tailed Student’s t test was used to determine statistical significance for all
bar charts except for the human AML patient data, which was preformed using
R (R Development Core Team, 2010). The log-rank test and Gehan-Breslow-
Wilcoxon test were used to compare survival curves. For the colony assays
comparison, a generalized linear model using a Poisson family with log link
using the glm function was used. For the comparison of GFP evolution over
time in MS5 cocultures, a negative binomial model, as implemented in glm.nb,
was used (package MASS) (Venables and Ripley, 2002). Analysis of deviance
tests were carried out with the appropriate call to function ANOVA. LDA plots
were produced using the limdil function of package statmod (Smyth et al.,
2010), together with a plotting function slightly modified using the plotrix
package (Lemon, 2006). p values less than 0.05 were considered statistically
significant..
Cancer Cell
b-Catenin in MLL Leukemia and Drug ResistanceACCESSION NUMBERS
Microarray data were deposited in the ArrayExpress public database at the
European Bioinformatic Institute (http://www.ebi.ac.uk/arrayexpress) with
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